- SMEs, academia, and research institutions. (Large Pharma companies are permitted to apply but must be ready to cover their own costs).
- Research into high-burden drug-resistant bacterial infections across LRTIs, UTIs, BSIs, IAIs, including pneumonia, sepsis, and bacteraemia.
- Bacterial infections associated with WHO critical priority Gram-negative pathogens Enterobacteriaceae (prioritising coli and K. pneumoniae), A. baumannii, P. aeruginosa, and high-priority Gram-positive infections (specifically S. aureus oral route).
- Hit validation, Hit-to-lead, or Lead optimisation stage.
- A clear focus on novel, targeted therapeutics only, but can be modality agnostic.
- Can include direct, indirect-acting, potentiators and anti-virulence approaches.
Posted 03 / 08 / 23